Ionis Pharma announces publication in The New England Journal of Medicine of key preclinical findings with angiopoietin-like 3 (ANGPTL3)-targeting drugs and Phase 1/2 clinical study results with AKCEA-ANGPTL3-LRx:
The study resulted in substantial, dose-dependent reductions in multiple lipids and lipoproteins, including triglycerides, LDL cholesterol, apolipoprotein B, non-HDL cholesterol and apolipoprotein C-III.
•AKCEA-ANGPTL3-LRx was well tolerated with no serious adverse events.
•Ionis and Akcea are developing AKCEA-ANGPTL3-LRx, to treat rare hyperlipidemias, non-alcoholic fatty liver disease (NAFLD) and combined dyslipidemias to potentially prevent and treat cardiovascular disease.
No comments:
Post a Comment